Current Trends in Breast Cancer Pathology, Screening, Diagnosis and Treatments.

Format:

Book

Author/Creator:

Khan, Firdos Alam.

Language:

English

Subjects (All):

Breast.

Physical Description:

1 online resource (605 pages)

Edition:

1st ed.

Place of Publication:

Chantilly : Elsevier Science & Technology, 2026.

Summary:

Cutting-edge Computational Intelligence in Healthcare with Convolution and Kronecker Convolution-based Approaches discusses how advanced deep learning techniques enhance medical image analysis.

Contents:

Front Cover

Current Trends in Breast Cancer Pathology, Screening, Diagnosis and Treatments

Copyright Page

Contents

List of contributors

About the editor

Preface

Acknowledgments

1 Breast cancer: definition, history, symptoms, causes, worldwide scenario, global statistics

1.1 Historical perspectives

1.1.1 Religious impact on breast cancer treatment

1.1.2 Beginning of surgical intervention

1.1.3 Surgical innovation

1.1.4 Modern approach in cancer treatment

1.2 Breast cancer symptoms

1.3 Causes of breast cancer

1.4 Risk factors for breast carcinoma

1.5 Genetics of breast cancer: BRCA1 and BRCA2

1.6 Breast cancer statistics and global scenario

References

Further reading

2 Current trends in breast cancer: pathology, breast cancer microscopic analysis, breast cancer stages, and classification

2.1 Introduction

2.2 Breast anatomy

2.3 Arterial supply of breast

2.4 Nerve supply of the breast

2.5 Breast parenchyma: structure and function

2.6 Pathophysiology of breast cancer

2.6.1 Initiation

2.6.2 Tumor formation

2.6.3 Hormonal influences

2.6.4 Angiogenesis

2.6.5 Metastasis

2.6.6 Immune evasion

2.7 Genetics of breast cancer

2.7.1 Tumor suppressor genes

2.7.1.1 BRAC1

2.7.1.2 BRCA2 gene

2.7.1.3 Tumor protein P53 gene

2.7.1.4 Ataxia telangiectasia mutated gene

2.7.1.5 CHEK-2 gene

2.7.1.6 BRCA1 interacting protein C-terminal helicase 1 gene

2.7.1.7 Partner and localizer of BRCA2 gene (PALB2)

2.7.2 Tumor-promoting genes

2.7.2.1 HER2

2.7.2.2 PIK3CA

2.7.2.3 MYC

2.7.2.4 CCND1

2.7.2.5 Fibroblast growth factor receptor 1

2.7.3 Sporadic breast cancer

2.7.4 Gene environment interactions

2.8 Classification of breast cancer

2.8.1 Histological classification of breast cancer

2.8.1.1 Noninvasive carcinoma (in situ).

2.8.1.2 Lobular carcinoma in situ

2.8.2 Ductal carcinoma in situ

2.8.3 Invasive carcinoma

2.8.4 Invasive lobular carcinoma

2.8.4.1 Invasive ductal carcinoma

2.9 Molecular classification of breast cancer

2.9.1 Luminal A

2.9.2 Luminal B

2.9.3 HER2 positive

2.9.4 Triple negative

2.10 Microscopic techniques for breast cancer analysis

2.10.1 Nonlinear microscopy

2.10.2 Normal breast tissue

2.10.2.1 Ductal carcinoma in situ

2.10.2.2 Invasive carcinoma

2.10.3 Fluorescence microscopy

2.10.4 Atomic force microscopy

2.10.5 Second harmonic generation microscopy

2.11 Summary

3 Role of Molecular Genetics and Epigenetics in Breast Cancer

3.1 Breast cancer

3.1.1 Histology and tissue architecture of the mammary gland

3.1.2 Histological subtypes of breast cancer

3.1.3 Ductal carcinoma in situ

3.1.4 Invasive ductal carcinoma

3.1.5 Lobular carcinoma in situ

3.1.6 Invasive lobular carcinoma

3.1.7 Molecular subtypes of breast cancer

3.1.8 Luminal tumors

3.1.9 Luminal A

3.1.10 Luminal B

3.1.11 Human epidermal growth factor receptor 2-positive breast cancer

3.1.12 Triple negative breast cancer

3.1.13 Genetic mutations involved in breast cancer

3.1.14 Breast cancer genes with high penetrance

3.1.15 TP53 (Li-Fraumeni syndrome)

3.1.16 PTEN (a homolog of phosphatase tensin)

3.1.17 Breast cancer genes with moderate penetrance

3.1.18 HER2/ERRB2

3.1.19 Epidermal growth factor receptor

3.1.20 c-Myc

3.1.21 RAS

3.1.22 Signaling pathways in breast cancer

3.1.22.1 NF-κB signaling pathway

3.1.23 Transforming growth factor-β

3.1.24 PI3/AKT/mTOR signaling pathway

3.1.25 Notch signaling pathway

3.1.26 Wnt signaling pathway

3.1.27 Epigenetic changes in breast cancer

References.

4 Breast cancer diagnosis: an overview of cellular, molecular, and genetic testing techniques

4.1 Introduction

4.2 Types of breast cancer

4.2.1 Noninvasive breast cancer

4.2.1.1 Ductal carcinoma in situ

4.2.1.2 Lobular carcinoma in situ

4.2.2 Invasive breast cancer

4.2.2.1 Invasive ductal carcinoma

4.2.2.2 Invasive lobular carcinoma

4.2.2.3 Inflammatory breast cancer

4.2.2.4 Triple-negative breast cancer

4.2.2.5 HER2-positive breast cancer

4.2.2.6 Hormone receptor-positive breast cancer

4.2.2.7 Metaplastic breast cancer

4.3 Diagnosis of breast cancer

4.3.1 Imaging techniques

4.3.2 Clinical examination

4.3.3 Biomarker analysis

4.3.4 Other biomarkers

4.4 Breast cancer biomarkers

4.4.1 Aldehyde dehydrogenase 1 family member A1

4.4.2 Schlafen family member 11

4.4.3 Tumor protein P53

4.4.4 Epidermal growth factor receptor

4.4.5 Cytokeratins 7 and 20

4.5 Treatment of breast cancer

4.5.1 Surgery

4.5.2 Radiation therapy

4.5.3 Chemotherapy

4.5.4 Hormone therapy

4.5.5 Targeted therapy

4.5.6 Immunotherapy

4.5.7 Clinical trials

4.6 Prevention of breast cancer

4.6.1 Lifestyle modifications

4.6.2 Genetic counseling and testing

4.6.3 Medical interventions

4.6.4 Breastfeeding

4.6.5 Environmental factors

4.7 Ongoing research and emerging technologies in breast cancer

4.7.1 Liquid biopsies

4.7.2 Artificial intelligence and deep learning

4.7.3 Breast cancer stem cells

4.8 Patient follow-up and monitoring

4.8.1 Traditional follow-up methods

4.8.1.1 Detect recurrence

4.8.1.2 Monitor treatment effects

4.8.1.3 Provide supportive care

4.9 Integration of omics data

4.9.1 Genomics

4.9.2 Proteomics

4.9.3 Transcriptomics

4.9.4 Metabolomics

4.9.5 Multiomics integration

4.10 Conclusion

Acknowledgments.

Conflicts of interest

5 Breast cancer treatment using surgical intervention: methods, advantages, and disadvantages of surgical intervention

5.1 Introduction

5.2 Surgical interventions for breast cancer

5.2.1 Breast-conserving therapy

5.3 Partial mastectomy

5.4 Oncoplastic surgery

5.4.1 Mastectomy

5.5 Bariatric surgery

6 Breast cancer treatment using chemotherapy methods, advantages, and disadvantages of chemotherapy

6.1 Introduction

6.2 When should chemotherapy be used in early breast cancer?

6.3 How chemotherapy is used in early breast cancer?

6.4 Which chemotherapy should be used in early breast cancer?

6.4.1 Taxanes

6.4.2 Dose-dense chemical therapy

6.5 Chemotherapy targets

6.5.1 Targeting HER2

6.5.1.1 Trastuzumab

6.5.1.2 Lapatinib

6.5.1.3 Pertuzumab

6.5.2 Targeting Vascular Endothelial Growth Factor

6.6 Advancements in chemotherapy of breast carcinoma

6.7 Advantages of chemotherapy in breast cancer

6.8 Disadvantages of chemotherapy

6.8.1 Ovarian insufficiency and fertility

6.8.2 Peripheral neuropathy

6.8.3 Nephrotoxicity

6.8.4 Cardiotoxicity

6.8.5 Alopecia

6.9 Conclusion

7 Breast cancer treatment using radiation therapy, advantages, and disadvantages of radiation therapy

7.1 Introduction

7.2 Understanding radiation therapy

7.3 Types of radiation therapy for breast cancer

7.3.1 External beam radiation therapy

7.3.1.1 Techniques in external beam radiation therapy

7.3.1.2 Scheduling and fractionation

7.3.1.3 Toxicity management and advances

7.3.2 Internal beam radiation therapy (brachytherapy)

7.3.2.1 Types of brachytherapy for breast cancer

7.3.2.2 Accelerated partial breast irradiation

7.3.3 Advantages and indications for brachytherapy.

7.3.4 Clinical outcomes and research in brachytherapy

7.3.5 Challenges and future directions

7.4 How radiation therapy is administered (treatment planning, treatment delivery)

7.5 Advantages of radiation therapy to deliver

7.5.1 Combined radiotherapy and chemotherapy for breast cancer

7.5.2 Mechanism and rationale

7.5.3 Treatment protocols and sequencing

7.5.4 Benefits of combination therapy

7.5.4.1 Improved local control

7.5.4.2 Increased survival rates

7.5.4.3 Reduced need for mastectomy

7.5.4.4 Better prognosis for hormone receptor-positive patients

7.5.5 Challenges and toxicity management

7.5.6 Future directions and research

7.5.7 Radiation therapy in breast conservation

7.5.8 Role of radiation therapy in second primary cancer risk reduction

7.6 Disadvantages of radiation therapy

7.6.1 Risk of ischemic heart disease in women after radiotherapy for breast cancer

7.6.2 Potential for acute coronary events

7.6.3 Limitations in treatment choices for high-risk patients

7.6.4 Secondary cancer risks

7.6.5 Breast changes and physical alterations

7.6.6 Lymphedema

7.6.7 Cognitive and psychological effects

7.6.8 Persistent fatigue

7.7 Conclusion

8 Breast cancer treatment using immunotherapy, advantages and disadvantages of immunotherapy

8.1 Introduction

8.2 Mechanism of immunotherapy in breast cancer

8.2.1 Immune checkpoint pathways

8.2.2 Tumor microenvironment and immune evasion

8.2.3 Role of biomarkers and immunogenomics

8.3 Immunotherapy strategies in breast cancer

8.3.1 Monoclonal antibodies

8.3.1.1 HER2 receptor inhibitor

8.3.1.1.1 Trastuzumab

8.3.1.1.2 Pertuzumab

8.3.1.1.3 Margetuximab

8.3.1.1.4 Pertuzumab

8.3.1.1.5 Lapatinib

8.3.1.1.6 Neratinib

8.3.1.2 CDK4/6

8.3.1.3 Angiogenesis inhibitor.

8.3.2 Antibody drug conjugate.

Notes:

Description based on publisher supplied metadata and other sources.

ISBN:

0-443-33348-3

9780443333484

OCLC:

1569750907